Vontobel Holding Ltd. Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Vontobel Holding Ltd. increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 12.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,278 shares of the biotechnology company’s stock after buying an additional 2,863 shares during the period. Vontobel Holding Ltd.’s holdings in Sarepta Therapeutics were worth $2,438,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Montag A & Associates Inc. purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC raised its position in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Sarepta Therapeutics in the 3rd quarter valued at approximately $33,000. KB Financial Partners LLC acquired a new stake in Sarepta Therapeutics during the 1st quarter valued at $36,000. Finally, Fifth Third Bancorp increased its position in Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock worth $96,000 after buying an additional 924 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on SRPT. UBS Group upped their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Needham & Company LLC lowered their price target on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating for the company in a report on Thursday, February 29th. TheStreet raised shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 4th. Finally, Royal Bank of Canada lifted their target price on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $158.38.

Insider Buying and Selling

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Sarepta Therapeutics news, Director Stephen Mayo sold 3,135 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total value of $385,479.60. Following the completion of the transaction, the director now owns 6,621 shares in the company, valued at approximately $814,118.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. In the last three months, insiders sold 22,096 shares of company stock valued at $2,739,419. Company insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Stock Down 1.1 %

Shares of NASDAQ:SRPT opened at $116.55 on Friday. The stock has a 50-day simple moving average of $126.75 and a 200-day simple moving average of $110.43. The stock has a market capitalization of $10.94 billion, a P/E ratio of -19.04 and a beta of 0.94. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $159.89. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. During the same period in the previous year, the company posted ($1.24) earnings per share. Sarepta Therapeutics’s revenue was up 53.6% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.14 earnings per share for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.